Published in final edited form as:

Bioorg Med Chem Lett. 2007 November 1; 17(21): 5783–5789.

N⁴-Phenyl Modifications of N²-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines Enhance Glucocerebrosidase Inhibition by Small Molecules with Potential as Chemical Chaperones for Gaucher Disease

Wenwei Huang^a, Wei Zheng^a, Daniel J. Urban^b, James Inglese^a, Ellen Sidransky^{*,b}, Christopher P. Austin^a, and Craig J. Thomas^{*,a}

^aNIH Chemical Genomics Center, National Human Genome Research Institute, NIH, 9800 Medical Center Drive, MSC 3370 Bethesda, MD 20892-3370 USA

^bMedical Genetics Branch, National Human Genome Research Institute, NIH, Bld 35 Rm1A213, 35 Convent Drive, Bethesda, MD 20892-3708 USA.

Abstract

A series of 1,3,5-triazine-2,4,6-triamines were prepared and analyzed as inhibitors of glucocerebrosidase. Synthesis, structure activity relationships and the selectivity of chosen analogues against related sugar hydrolases enzymes are described.

Glycosphingolipids are cell membrane components that maintain the stability of the lipid bilayer, function as cellular recognition elements and play an important role in cellular adherence.¹ These important cellular constructs are comprised of varying polysaccharide chains linked to ceramide via a glycosidic bond. Glycosphingolipids are ultimately targeted for degradation through the action of selected lysosomal hydrolases.² Several different diseases arise when a defect in one or more of these hydrolases causes non-degraded glycosphingolipids to accumulate within the lysosome.³ These maladies are commonly referred to as “lysosomal storage disorders”, and include Niemann-Pick, Tay-Sachs and Gaucher disease.

Gaucher disease results from mutations in the glucocerebrosidase (GC) gene. Many of these are point mutations that result in a misfolded protein with diminished catalytic activity or aberrant trafficking from the endoplasmic reticulum to the lysosome.^{2,3} Over 200 different mutations giving rise to Gaucher disease have been identified, and it is likely that multiple misfolded protein conformations exist.⁴ Current treatment for Gaucher disease involves enzyme replacement therapy.⁵ While this therapy alleviates many of the systemic manifestations of the disease including hepatosplenomegaly, anemia and thrombocytopenia, the inability of recombinant enzyme to cross the blood brain barrier prevents amelioration of the CNS associated symptoms in neuronopathic forms of Gaucher disease. The subset of mutations that result in protein misfolding and improper trafficking of GC to the lysosome

*Send proofs to: Craig J. Thomas, Ph.D, Chemistry Group Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, NIH, 9800 Medical Center Drive, MSC 3370, Bethesda, MD 20892-3370 USA, Phone: 301-217-4079; Fax: 301-217-5736, email: craigt@mail.nih.gov; Ellen Sidransky M.D., Chief, Section on Molecular Neurogenetics, MGB, National Human Genome Research Institute, NIH, Bld 35 Rm 1A-213, 35 Convent Drive, MSC 3708, Bethesda, MD 20892-3708, Phone: 301-451-0901 or 301-496-0373; Fax: 301-402-6438, email: sidranse@mail.nih.gov

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

presents an opportunity for the use of “chemical chaperone” therapy, and importantly could provide a therapeutic approach capable of penetrating the blood brain barrier.

Chemical chaperones are small molecules that bind to a misfolded proteins restoring correct structural conformation and enabling appropriate protein trafficking.⁶ Once the chaperoned protein reaches its appropriate subcellular location, the small molecule chaperone must either be displaced by native substrate to allow for the continued presence of a correctly folded, active protein, or bind to an allosteric site that does not disrupt substrate binding. The utility of chaperone therapy in Gaucher, Sandhoff, Fabry and Tay-Sachs diseases has been studied.^{7,8} Kelly and coworkers⁹, Overkleeft and coworkers¹⁰ and Fan and coworkers¹¹ have advanced several iminosugars designed to mimic the native glycosphingolipid substrate as potential GC chaperones. Several of these small molecules are currently being evaluated in clinical trials.⁸ In addition, at least one reported non-sugar based small molecule (1-pheyny-2-decanoylamino-3-morpholino-1-propanol), which was designed as a ceramide mimic, is also being studied clinically.⁸ We recently reported the use of qHTS to identify three novel, structurally distinct small molecule inhibitors of GC including 2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol (**1**), *N*-(4-methyl-2-morpholinoquinolin-6-yl)cyclohexanecarboxamide (**2**) and *N*-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(phenylsulfonamido)benzamide (**3**) (Figure 1).¹² These novel GC inhibitors possess potencies comparable to the best iminosugars, including the clinically relevant *N*-butyl-deoxynojirimycin (Miglustat) (**4**) [for **1**: IC₅₀ = 0.70 μM; for **2**: IC₅₀ = 0.031 μM; for **3**: IC₅₀ = 0.070 μM]. A significant property of these structures is their apparent selectivity versus related sugar hydrolases including α-glucosidase, α-glucosidase and β-hexosaminidase.

It has been demonstrated that the ability of iminosugars to act as chemical chaperones is dependent upon the nature of the specific mutant protein.¹³ Further, Kelly and coworkers have shown that temperature alterations have differential effects on the cellular trafficking of selected GC variants.¹⁴ These studies suggest that differing mutant forms of GC likely result in distinctive protein misfolding. Taken together with the vast number of clinically relevant GC mutations, these findings emphasize the value of developing divergent small molecule chemotypes to target alternant folded proteins.

Previously, we evaluated the ability of these novel GC inhibitors to act as chemical chaperones and found that the least potent structural series (the 1,3,5-triazine-2,4,6-triamine core represented by **1**) possessed the greatest chaperone activity.¹² This intriguing finding prompted us to further explore and optimize this series of compounds. To this end, we synthesized and evaluated numerous analogues of **1** by examining three discrete sections of the compounds; the aminoethanol moiety, the pyrrolidinyl moiety and the substituted aniline moiety.

The synthetic methods for the construction of substituted triazines are well documented.¹⁵ We utilized a three step, one pot procedure (Scheme 1) whereby cyanuric chloride is treated first with substituted aniline (see Table 3) in acetonitrile with (method B) or without (method A) Hunig's base.¹⁶ Following this transformation, primary or secondary amines (see Table 2) were administered in either 3.3 equivalence (method A) or 1.1 equivalence (method B) in DMA with Hunig's base for 10 minutes. Finally, a large excess of primary and secondary alkyl and cycloalkylamines (see Table 1) was added and stirred for 4 to 8 hours and the resulting mixture was purified via mass-directed preparative HPLC. Yields for the one pot, three step procedure were typically in excess of 60%. Each construct was examined by LCMS and ELSD for purity and characterized via ¹H NMR, high-resolution mass spectrometry and ¹³C NMR for selected analogues.¹⁷ Individual compounds were evaluated biochemically¹⁸ from standard 10 μM DMSO solutions via a GC enzyme assay utilizing a fluorogenic resorufin β-D-glucopyranoside substrate as previously reported.¹²

Our first investigations addressed the SAR of the ethanolamine moiety (Table 1). The qHTS screen revealed **1** as a potent inhibitor of GC from a collection of nearly 400 related triazine structures that did not maintain an ethanolamine moiety. As anticipated, our subsequent attempts to modify this substructure were collectively detrimental. It was also noted that deviations from any substructure that did not contain a hydroxyl group conferred difficulty with water solubility. This observation is supported by the calculated cLogP values of selected analogues as illustrated by the comparison of **1** (calculated cLogP of 3.35) with **7** (calculated cLogP of 5.23). Additional compounds were made and examined including the 2-aminoethyl analogue and showed no apparent activity (data is not shown due to insufficient purity analysis - typically less than 80% pure by HPLC UV/Vis peak integration).

We next attempted to optimize the inhibitory potential of this series through alterations at the pyrrolidinyl moiety (Table 2). Here again, deviations from this core component were found to be adverse in terms of GC inhibition. Interestingly, altering a pyrrolidinyl to a *N,N*-diethylamino moiety (analogue **18**) that maintained the same relative size, yet lost the rigid ring structure, resulted in an analogue that was completely inactive. Rings of a larger size (6 and more) were significantly less potent and the only smaller ring system explored (the 4-membered azetidiny ring) was modestly potent, yet significantly less than the core pyrrolidinyl moiety found in **1** and **31**.

Finally, optimizations of the aniliny moiety were examined (Table 3). Within this substructure we first focused on the existing 2-methoxy, 5-chloro substitution pattern by exploring selected replacements and deletions in terms mono- versus di-substitution and relative position (ortho, meta and para). While the majority of these analogues (for example **28-30**, **31-34**) remained modestly potent, none surpassed the original ligand. We also explored various commonly applied substitutions including methyl (analogues **25-27**) di-methoxy (analogues **41**, **42**) and trifluoromethoxy (analogue **39**) with limited success. We next investigated the consequence of altering a 2-OMe group (analogue **31**) to a 2-OEt group (analogue **35**). This change resulted in a modest potency enhancement relative to the mono-substituted 2-OMe analogue. We further evaluated this trend by expanding this moiety into a 2-OPh (analogue **36**) and 2-OrBu (analogue **37**). Gratifyingly, **37** provided an IC₅₀ value of 0.33 μ M, the lowest reported potency for this structural class of GC inhibitors. Unfortunately, this SAR was not found to be enhanced by incorporation of the previously noted disubstituted analogues containing a 5-Cl substitution in conjugation with the 2-alkoxy series (analogues **50-52**). Continued explorations also revealed that a 2-OH, 5-Ph substitution (analogue **49**) conferred an IC₅₀ value of 0.37 μ M. Thus, the two most potent analogues possessed structurally unrelated substitution patterns, and only modestly related calculated cLogP values (calculated cLogP of 3.72 for **37** and calculated cLogP of 4.22 for **49**). Efforts to ascertain the binding site through co-crystallization and docking studies will be pursued.

Having found novel analogues with improved potency, it was important to confirm that they maintained the selectivity profile of the parent compound (**1**) versus the related hydrolases α -glucosidase, α -galactosidase and β -hexosaminidase.¹⁸ Importantly, **37** showed no activity against any of these related enzymes at concentrations up to 77 μ M (Figure 2).

Through manipulations of the *N*⁴-phenyl moiety, we optimized the inhibitory activity of a small molecule shown to possess strong chemical chaperone activity and arrived at novel analogue **37** with an IC₅₀ value of 330 nM. The expanded compound set provides numerous analogues with GC enzyme inhibitory potencies ranging from 0.3 μ M and 2.0 μ M. This family of inhibitors, as well as those from ongoing studies based upon **2** and **3**, will enable us to probe the relationship between enzymatic inhibitory potency and chaperone activity. Expanded compound sets of divergent structures that maintain a range of potencies may represent crucial probe compounds that will permit further characterization of various GC mutants. Moreover,

since different mutant forms of GC are likely to require different chemical chaperones, these expanded compound sets will facilitate exploration of the potential for mutation-specific chemical chaperones.

Acknowledgments

The authors would like to thank Jeremy Smith, Adam Yasgar and Paul Shinn for assistance in compound management. The authors would like to thank Bryan Mott for helpful discussion and critical reading of this manuscript. Thanks also to Bev Chamberlin at MSU Mass Spectrometry Facility for HRMS analyses. This research was supported by the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.

References and notes

- (1). Wedeking A, van Echten-Deckert G. *Curr. Org. Chem* 2007;11:579.
- (2). Sawker AR, D'Haeze W, Kelly JW. *Cell. Mol. Life Sci* 2006;63:1179. [PubMed: 16568247]
- (3). Futerman AH, van Meer G. *Nat. Rev. Mol. Cell. Biol* 2004;5:554. [PubMed: 15232573]
- (4). Hruska, KS.; LaMarca, ME.; Sidransky, E. *Gaucher Disease*. Futerman, AH.; Zimran, A., editors. CRC Press; Boca Raton, FL: 2006. p. 13
- (5). Barton NW, Brady RO, Dambrosia JM, Dibisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. *N. Engl. J. Med* 1991;324:1464. [PubMed: 2023606]
- (6). Sawker AR, Cheng W-C, Beutler W, Wong C-H, Balch WE, Kelly JW. *Proc. Natl. Acad. Sci. U.S.A* 2002;99:15428. [PubMed: 12434014]
- (7). Fan J-Q. *Trends Pharmacol. Sci* 2003;24:355. [PubMed: 12871668]
- (8). Butters TD. *Expert Opin. Pharmacother* 2007;8:427. [PubMed: 17309337]
- (9). Yu Z, Sawker AR, Whalen LJ, Wong C-H, Kelly JW. *J. Med. Chem* 2007;50:94. [PubMed: 17201413]
- (10). Wennekes T, van der Berg RJBHN, Donker W, van der Marel GA, Strijland A, Aerts JMFG, Overkleef HS. *J. Org. Chem* 2007;72:1088. [PubMed: 17243712]
- (11). Zhu X, Sheth KA, Li S, Chang H-H, Fan J-Q. *Angew. Chem. Int. Ed* 2005;44:7450.
- (12). Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, Simeonov A, Goldin E, Auld D, LaMarca ME, Inglese J, Austin CP, Sidransky E. *Proc. Natl. Acad. Sci. U.S.A* 2007;104:13192. [PubMed: 17670938]
- (13). Sawker AR, Adamski-Werner SL, Cheng W-C, Wong C-H, Beutler E, Zimmer K-P, Kelly JW. *Chem. Biol* 2005;12:1235. [PubMed: 16298303]
- (14). Sawker AR, Schmitz M, Zimmer K-P, Reczek D, Edmunds T, Balch WE, Kelly JW. *ACS Chem. Biol* 2006;1:235. [PubMed: 17163678]
- (15). Katiyar SB, Srivastava K, Puri SK, Chauhan PMS. *Bioorg. Med. Chem. Lett* 2005;15:4957. [PubMed: 16168643]
- (16). The majority of substituted anilines were commercially available. However 5-chloro-2-ethoxyaniline, 5-chloro-2-isopropoxyaniline, 2-tert-butoxyaniline and 2-tert-butoxy-5-chloroaniline required independent syntheses. The method was modified from a procedure by Wandless and coworkers WoiwodeTFRoseCWandlessTJJ. *Org. Chem* 1998;63:9594 Substituted anilines were utilized directly following a purifying extraction

- (17). Spectroscopic data for **1**, **5-53** [Note: Several peaks within the proton and carbon NMR spectrum existed as rotomers that coalesce upon heating to 60 °C. This is a well established phenomenon associated with triazine scaffolds (see Arvanitis J. Med. Chem 1999;42:3852. [PubMed: 10072679] Hajduk, et al. J. Med. Chem 1999;42:3852. [PubMed: 10508434] and Leftheris, et al. J. Med. Chem 2004;47:6283. [PubMed: 15566298] for examples)]: **1**¹H NMR (400 MHz, DMSO-d₆) δ 8.64 (d, 1H, J = 6.6 Hz), 7.37-7.28 (m, 1H), 7.05-6.94 (m, 3H), 4.74-4.66 (m, 1H), 3.90 (s, 3H), 3.60-3.33 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): *m/z* calcd for C₁₆H₂₁ClN₆O₂ [M+1]⁺ 365.1493, found 365.1492. **5**¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (d, 1H, J = 2.3 Hz), 7.39-7.28 (m, 1H), 7.05-6.98 (m, 3H), 3.91 (s, 3H), 3.51-3.30 (m, 11H), 1.91 (bs, 4H); HRMS (ESI): *m/z* calcd for C₁₇H₂₃ClN₆O₂ [M+1]⁺ 379.1649, found 379.1644. **6**¹H NMR (400 MHz, DMSO-d₆) δ 8.60 (d, 1H, J = 2.3 Hz), 7.36 (s, 1H), 7.05 (d, 1H, J = 8.8 Hz), 6.99 (dd, 1H, J = 8.6, 2.5 Hz), 4.80-4.77 (m, 2H), 3.91 (s, 3H), 3.66 (bs, 8H), 3.56-3.46 (m, 4H), 1.93 (bs, 4H); HRMS (ESI): *m/z* calcd for C₁₈H₂₅ClN₆O₃ [M+1]⁺ 409.1755, found 409.1766. **7**¹H NMR (400 MHz, DMSO-d₆) δ 8.68-8.62 (m, 1H), 7.35-7.24 (m, 1H), 7.16-6.97 (m, 3H), 3.91 (s, 3H), 3.51-3.27 (s, 6H), 1.91 (bs, 4H), 1.57-1.50 (m, 2H), 1.42-1.32 (m, 2H), 0.93 (t, 3H, J = 7.4 Hz); HRMS (ESI): *m/z* calcd for C₁₈H₂₅ClN₆O [M+1]⁺ 377.1857, found 377.1860. **8**¹H NMR (400 MHz, DMSO-d₆) δ 8.62-8.56 (m, 1H), 7.74-7.62 (m, 1H), 7.39-7.20 (m, 6H), 7.04-6.97 (m, 2H), 4.51-4.49 (m, 2H), 3.90 (bs, 3H), 3.49-3.27 (m, 4H), 1.92 (s, 4H); HRMS (ESI): *m/z* calcd for C₂₁H₂₃ClN₆O [M+1]⁺ 411.1700, found 411.1709. **9**¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (d, 1H, J = 2.5 Hz), 7.38-7.28 (m, 1H), 7.05-6.97 (m, 3H), 4.06-3.98 (m, 1H), 3.90 (s, 3H), 3.82-3.28 (m, 8H), 1.96-1.78 (m, 7H), 1.68-1.58 (m, 1H); HRMS (ESI): *m/z* calcd for C₁₉H₂₅ClN₆O₂ [M+1]⁺ 405.1806, found 405.1800. **10**¹H NMR (400 MHz, DMSO-d₆) δ 8.62 (d, 1H, J = 2.5 Hz), 7.30 (s, 1H), 7.05-6.97 (m, 2H), 6.59 (bs, 2H), 3.90 (s, 3H), 3.52-3.38 (m, 4H), 1.92 (bs, 4H); HRMS (ESI): *m/z* calcd for C₁₄H₁₇ClN₆O [M+1]⁺ 321.1231, found 321.1237. **11**¹H NMR (400 MHz, DMSO-d₆) δ 8.47-8.44 (m, 1H), 7.96-7.90 (m, 1H), 7.35-7.26 (m, 1H), 7.04-6.93 (m, 4H), 3.90 (s, 3H), 3.51-3.22 (m, 8H), 1.91 (bs, 4H), 1.83 (s, 3H); HRMS (ESI): *m/z* calcd for C₁₈H₂₅N₇O₂ [M+1]⁺ 372.2148, found 372.2147. **12**¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, 1H, J = 7.2 Hz), 7.33-7.26 (m, 1H), 7.05-6.80 (m, 4H), 4.84-4.68 (m, 1H), 3.90 (bs, 3H), 3.89-3.68 (m, 1H), 3.60-3.17 (m, 6H), 1.91 (bs, 4H), 1.09 (d, 3H, J = 6.3 Hz); HRMS (ESI): *m/z* calcd for C₁₇H₂₄N₆O₂ [M+1]⁺ 345.2039, found 345.2041. **13**¹H NMR (400 MHz, DMSO-d₆) δ 8.48-8.39 (m, 1H), 7.39-7.24 (m, 6H), 7.08-6.80 (m, 4H), 5.63-5.44 (m, 1H), 4.86-4.76 (m, 1H), 3.90 (bs, 3H), 3.60-3.22 (m, 6H), 1.96-1.86 (m, 4H); HRMS (ESI): *m/z* calcd for C₂₂H₂₆N₆O₂ [M+1]⁺ 407.2195, found 407.2188. **14**¹H NMR (400 MHz, DMSO-d₆) δ 8.48-8.41 (m, 1H), 7.36-7.26 (m, 2H), 7.04-6.90 (m, 5H), 3.90 (s, 3H), 3.82 (d, 2H, J = 6.1 Hz), 3.58-3.34 (m, 4H), 1.91 (bs, 4H); HRMS (ESI): *m/z* calcd for C₁₆H₂₁N₇O₂ [M+1]⁺ 344.1835, found 344.1838. **15**¹H NMR (400 MHz, DMSO-d₆) δ 8.50-8.47 (m, 1H), 7.31-7.21 (m, 1H), 7.02-6.94 (m, 4H), 4.41 (bs, 1H), 3.90 (bs, 3H), 3.54-3.24 (m, 8H), 1.90 (s, 4H), 1.62-1.44 (m, 4H); HRMS (ESI): *m/z* calcd for C₁₈H₂₆N₆O₂ [M+1]⁺ 359.2195, found 359.2192. **16**¹H NMR (400 MHz, DMSO-d₆) δ 8.45-8.30 (m, 1H), 7.44-7.36 (m, 2H), 7.05-6.89 (m, 3H), 4.01-3.96 (m, 2H), 3.89 (s, 3H), 3.66 (s, 3H), 3.54-3.36 (m, 4H), 1.94-1.86 (m, 4H); HRMS (ESI): *m/z* calcd for C₁₇H₂₂N₆O₃ [M+1]⁺ 359.1832, found 359.1838. **17**¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (s,

1H), 7.54-7.43 (m, 1H), 7.16-6.94 (m, 3H), 4.70 (bs, 1H), 3.89 (s, 3H), 3.71-3.35 (m, 12H); HRMS (ESI): m/z calcd for $C_{16}H_{21}ClN_6O_3$ $[M+1]^+$ 381.1442, found 381.1439. **18**¹H NMR (400 MHz, DMSO- d_6) δ 8.64-8.56 (m, 1H), 7.38-7.29 (m, 1H), 7.28-6.87 (m, 3H), 4.76-4.64 (m, 1H), 3.90 (s, 3H), 3.62-3.30 (m, 8H), 1.24-1.06 (m, 6H); HRMS (ESI): m/z calcd for $C_{16}H_{23}ClN_6O_2$ $[M+1]^+$ 367.1649, found 367.1647. **19**¹H NMR (400 MHz, DMSO- d_6) δ 8.50 (d, 1H, $J = 2.3$ Hz), 7.45-7.34 (m, 1H), 7.08-6.94 (m, 3H), 4.72-4.64 (m, 1H), 3.90 (s, 3H), 3.78-3.68 (m, 4H), 3.57-3.52 (m, 2H), 3.40-3.32 (m, 2H), 1.70-1.46 (m, 6H); HRMS (ESI): m/z calcd for $C_{17}H_{23}ClN_6O_2$ $[M+1]^+$ 379.1649, found 379.1659. **20**¹H NMR (400 MHz, DMSO- d_6) δ 8.62-8.56 (m, 1H), 7.38-7.28 (m, 1H), 7.06-6.86 (m, 3H), 4.72-4.64 (m, 1H), 3.91 (s, 3H), 3.71-3.28 (m, 8H), 1.81-1.68 (m, 4H), 1.58-1.46 (m, 4H); HRMS (ESI): m/z calcd for $C_{18}H_{25}ClN_6O_2$ $[M+1]^+$ 393.1806, found 393.1805. **21**¹H NMR (400 MHz, DMSO- d_6) δ 8.45-8.43 (m, 1H), 7.40-6.62 (m, 6H), 4.72 (bs, 1H), 3.89 (s, 3H), 3.53-3.26 (m, 6H), 1.58-1.48 (m, 2H), 1.40-1.30 (m, 2H), 0.93 (t, 3H, $J = 7.2$ Hz); HRMS (ESI): m/z calcd for $C_{16}H_{24}N_6O_2$ $[M+1]^+$ 333.2039, found 333.2046. **22**¹H NMR (400 MHz, DMSO- d_6) δ 8.45-8.20 (m, 1H), 7.64-7.20 (m, 7H), 7.06-6.74 (m, 4H), 4.80-4.64 (m, 1H), 4.51 (d, 2H, $J = 6.3$ Hz), 3.87 (bs, 3H), 3.56-3.30 (m, 4H); HRMS (ESI): m/z calcd for $C_{19}H_{22}N_6O_2$ $[M+1]^+$ 367.1882, found 367.1889. **23**¹H NMR (400 MHz, DMSO- d_6) δ 8.40-8.32 (m, 1H), 7.50-7.40 (m, 1H), 7.06-6.90 (m, 4H), 4.74-4.66 (m, 1H), 3.96-3.86 (m, 4H), 3.76-3.68 (m, 2H), 3.56-3.34 (m, 5H), 2.55-2.45 (m, 2H); HRMS (ESI): m/z calcd for $C_{16}H_{20}F_2N_6O_2$ $[M+1]^+$ 367.1694, found 367.1695. **24**¹H NMR (400 MHz, DMSO- d_6) δ 8.42-8.38 (m, 1H), 7.41-7.33 (m, 1H), 7.04-6.93 (m, 4H), 4.79-4.64 (m, 1H), 4.09-3.98 (m, 4H), 3.89 (s, 3H), 3.56-3.50 (m, 2H), 3.40-3.32 (m, 2H), 2.34-2.40 (m, 2H); HRMS (ESI): m/z calcd for $C_{15}H_{20}N_6O_2$ $[M+1]^+$ 317.1726, found 317.1723. **25**¹H NMR (400 MHz, DMSO- d_6) δ 8.10-7.94 (m, 1H), 7.70-7.50 (m, 1H), 7.20-7.13 (m, 2H), 7.04-6.96 (m, 1H), 6.64-6.48 (m, 1H), 4.78-4.56 (m, 1H), 3.58-3.24 (m, 8H), 2.25 (s, 3H), 1.87 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O$ $[M+1]^+$ 315.1933, found 315.1938. **26**¹H NMR (400 MHz, DMSO- d_6) δ 8.90-7.70 (m, 1H), 7.77-7.54 (m, 2H), 7.12 (t, 1H, $J = 7.6$ Hz), 6.75-6.60 (m, 2H), 4.78-4.67 (m, 1H), 3.58-3.34 (m, 8H), 2.29 (s, 3H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O$ $[M+1]^+$ 315.1933, found 315.1940. **27**¹H NMR (400 MHz, DMSO- d_6) δ 8.90-8.72 (m, 1H), 7.71 (d, 2H, $J = 8.6$ Hz), 7.06 (d, 2H, $J = 8.0$ Hz), 6.66 (bs, 1H), 4.82-4.60 (m, 1H), 3.58-3.28 (m, 8H), 2.26 (s, 3H), 1.90 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O$ $[M+1]^+$ 315.1933, found 315.1938. **28**¹H NMR (400 MHz, DMSO- d_6) δ 8.26-8.18 (m, 1H), 7.84-7.70 (m, 1H), 7.47 (dd, 1H, $J = 8.0, 1.6$ Hz), 7.32 (t, 1H, $J = 7.2$ Hz), 7.10-7.05 (m, 1H), 6.84-6.78 (m, 1H), 4.74-4.66 (m, 1H), 3.53-3.31 (m, 8H), 1.89 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{19}ClN_6O$ $[M+1]^+$ 335.1387, found 335.1396. **29**¹H NMR (400 MHz, DMSO- d_6) δ 9.23-9.11 (m, 1H), 8.16-8.10 (m, 1H), 7.71-7.69 (m, 1H), 7.26 (t, 1H, $J = 7.8$ Hz), 6.95 (d, 1H, $J = 7.2$ Hz), 6.83-6.77 (m, 1H), 4.75-4.65 (m, 1H), 3.58-3.36 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{19}ClN_6O$ $[M+1]^+$ 335.1387, found 335.1391. **30**¹H NMR (400 MHz, DMSO- d_6) δ 9.15-9.04 (m, 1H), 7.86 (d, 2H, $J = 8.8$ Hz), 7.29 (bs, 2H), 6.76 (bs, 1H), 4.76-4.67 (m, 1H), 3.56-3.32 (m, 8H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{19}ClN_6O$ $[M+1]^+$ 335.1387, found 335.1391. **31**¹H NMR (400 MHz, DMSO- d_6) δ 8.48-8.46 (m, 1H), 7.34-7.26 (m, 1H), 7.04-6.82 (m, 4H), 4.74-4.68 (m, 1H), 3.90 (s, 3H), 3.51-3.32 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O_2$ $[M+1]^+$ 331.1882, found 331.1883. **32**¹H NMR (400 MHz, DMSO- d_6) δ 8.97-8.85 (m, 1H), 7.77-7.69 (m, 1H), 7.36-7.20 (m, 1H), 7.13 (t, 1H, $J = 8.2$ Hz), 6.73-6.66 (m, 1H), 6.50 (dd, 1H, $J = 7.6, 1.8$ Hz), 4.77-4.66 (m, 1H), 3.76 (s, 3H), 3.71-3.32 (m, 8H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O_2$ $[M+1]^+$ 331.1882, found 331.1879. **33**¹H NMR (400 MHz, DMSO- d_6) δ 8.81-8.70 (m, 1H), 7.51 (d, 2H, $J = 8.2$ Hz), 6.85 (d, 2H, $J = 8.8$ Hz), 6.62 (bs, 1H), 4.77-4.66 (m, 1H), 3.74 (s, 3H), 3.69-3.32 (m, 8H), 1.90 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6O_2$ $[M+1]^+$ 331.1882, found 331.1888. **34**¹H NMR (400 MHz, DMSO- d_6) δ 10.68 (bs, 1H), 8.16-8.12 (m, 1H), 7.83-7.75 (m, 1H), 6.93-6.76 (m, 4H), 4.74-4.68 (m, 1H), 3.56-3.37 (m, 11H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{20}N_6O_2$ $[M+1]^+$ 317.1726, found 317.1729. **35**¹H NMR (400 MHz, DMSO- d_6) δ 8.50 (bs, 1H), 7.32-7.24 (m, 1H), 7.01-6.81 (m, 4H), 4.72 (bs, 1H), 4.20-4.13 (m, 2H), 3.56-3.34 (m, 8H), 1.91 (bs, 4H), 1.42 (t, 3H, $J = 7.8$ Hz); HRMS (ESI): m/z calcd for $C_{17}H_{24}N_6O_2$ $[M+1]^+$ 345.2039, found 345.2046. **36**¹H NMR (400 MHz, DMSO- d_6) δ 8.49 (d, 1H, $J = 8.0$ Hz), 7.54-7.36 (m, 3H), 7.19-7.14 (m, 2H), 7.10-6.98 (m, 3H), 6.94-6.86 (m, 1H), 6.82 (t, 1H, $J = 5.7$ Hz), 4.74-4.60 (m, 1H), 3.56-3.31 (m, 8H), 1.92-1.86 (m, 4H); HRMS (ESI): m/z calcd for $C_{21}H_{24}N_6O_2$ $[M+1]^+$ 393.2039, found 393.2033. **37**¹H NMR (400 MHz, DMSO- d_6) δ 8.57-8.49 (m, 1H), 7.34-7.25 (m, 1H), 7.12-7.03 (m, 2H), 6.93-6.84 (m, 2H), 4.76-4.64 (m, 1H), 3.57-3.34 (m, 8H), 1.91 (bs, 4H), 1.39 (s, 9H); ¹³C NMR (400 MHz, DMSO- d_6 , 60 °C)

δ 165.5, 163.2, 163.1, 143.3, 133.8, 122.8, 121.3, 120.6, 119.3, 79.6, 60.0, 45.4, 42.8, 28.4, 28.4, 24.4. HRMS (ESI): m/z calcd for $C_{19}H_{28}N_6O_2$ $[M+1]^+$ 373.2352, found 373.2356. **38**¹H NMR (400 MHz, DMSO- d_6) δ 8.47 (bs, 1H), 7.54-7.29 (m, 7H), 7.12-6.93 (m, 2H), 6.86-6.81 (m, 1H), 5.23-5.21 (m, 2H), 4.71-4.66 (m, 1H), 3.60-3.32 (m, 8H), 1.90 (bs, 4H); HRMS (ESI): m/z calcd for $C_{22}H_{26}N_6O_2$ $[M+1]^+$ 407.2195, found 407.2202. **39**¹H NMR (400 MHz, DMSO- d_6) δ 8.20 (d, 1H, J = 8.0 Hz), 8.10-7.96 (m, 1H), 7.38-7.33 (m, 2H), 7.18-7.13 (m, 1H), 6.77-6.75 (m, 1H), 4.72-4.63 (m, 1H), 3.48-3.33 (m, 8H), 1.89 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{19}F_3N_6O_2$ $[M+1]^+$ 385.1600, found 385.1602. **40**¹H NMR (400 MHz, DMSO- d_6) δ 8.12-8.07 (m, 1H), 7.88-7.83 (m, 1H), 7.49-7.40 (m, 1H), 7.25 (t, 1H, J = 7.4 Hz), 7.10-7.08 (m, 1H), 6.79 (t, 1H, J = 5.7 Hz), 4.72-4.65 (m, 1H), 3.52-3.30 (m, 8H), 2.42 (s, 3H), 1.90 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{22}N_6OS$ $[M+1]^+$ 347.1654, found 347.1659. **41**¹H NMR (400 MHz, DMSO- d_6) δ 8.25-8.10 (m, 1H), 7.21-7.16 (m, 1H), 6.75-6.60 (m, 2H), 6.51 (bs, 1H), 4.78-4.64 (m, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 3.57-3.26 (m, 8H), 1.94-1.84 (m, 4H); HRMS (ESI): m/z calcd for $C_{17}H_{24}N_6O_3$ $[M+1]^+$ 361.1988, found 361.1987. **42**¹H NMR (400 MHz, DMSO- d_6) δ 8.30-8.24 (m, 1H), 7.30-7.21 (m, 1H), 6.96-6.84 (m, 2H), 6.50 (dd, 1H, J = 8.8, 2.9 Hz), 4.78-4.64 (m, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 3.56-3.24 (m, 8H), 1.90 (bs, 4H); HRMS (ESI): m/z calcd for $C_{17}H_{24}N_6O_3$ $[M+1]^+$ 361.1988, found 361.1991. **43**¹H NMR (400 MHz, DMSO- d_6) δ 9.01-8.95 (m, 1H), 7.47-7.39 (m, 1H), 7.33 (d, 1H, J = 8.4 Hz), 7.21 (d, 1H, J = 8.4 Hz), 7.00-6.86 (m, 1H), 4.73-4.63 (m, 1H), 3.99 (s, 3H), 3.54-3.26 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{17}H_{21}F_3N_6O_2$ $[M+1]^+$ 399.1756, found 399.1760. **44**¹H NMR (400 MHz, DMSO- d_6) δ 8.99-8.87 (m, 1H), 7.66 (d, 2H, J = 7.4 Hz), 7.48-7.26 (m, 5H), 7.12 (d, 1H, J = 8.4 Hz), 6.88-6.83 (m, 1H), 4.60-4.49 (m, 1H), 3.95 (s, 3H), 3.60-3.40 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{22}H_{26}N_6O_2$ $[M+1]^+$ 407.2195, found 407.2192. **45**¹H NMR (400 MHz, DMSO- d_6) δ 9.58 (d, 1H, J = 7.2 Hz), 8.51-8.26 (m, 1H), 8.07 (t, 1H, J = 8.6 Hz), 7.72-7.67 (m, 1H), 7.22-7.17 (m, 1H), 6.93-6.87 (m, 1H), 4.78-4.65 (m, 1H), 3.58-3.28 (m, 8H), 1.89 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{19}N_7O_3$ $[M+1]^+$ 346.1628, found 346.1622. **46**¹H NMR (400 MHz, DMSO- d_6) δ 10.86-10.82 (m, 1H), 8.91-8.83 (m, 1H), 8.18 (s, 1H), 7.74 (dd, 1H, J = 8.0, 1.6 Hz), 7.60 (s, 1H), 7.48-7.44 (m, 1H), 7.00-6.82 (m, 2H), 4.72-4.70 (m, 1H), 3.57-3.33 (m, 8H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{16}H_{21}N_7O_2$ $[M+1]^+$ 344.1835, found 344.1839. **47**¹H NMR (400 MHz, DMSO- d_6) δ 9.78-9.70 (m, 1H), 8.13-8.01 (m, 1H), 7.85 (s, 1H), 7.43 (d, 1H, J = 7.6 Hz), 7.17-7.03 (m, 2H), 6.82-6.77 (m, 1H), 4.71-4.65 (m, 1H), 3.51-3.33 (m, 8H), 2.10 (s, 3H), 1.89 (bs, 4H); HRMS (ESI): m/z calcd for $C_{17}H_{23}N_7O_2$ $[M+1]^+$ 358.1991, found 358.1994. **48**¹H NMR (400 MHz, DMSO- d_6) δ 10.83 (bs, 1H), 8.19-8.09 (m, 1H), 7.90 (bs, 1H), 7.04-6.83 (m, 3H), 4.82-4.60 (m, 1H), 3.61-3.24 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{19}ClN_6O_2$ $[M+1]^+$ 351.1336, found 351.1334. **49**¹H NMR (400 MHz, DMSO- d_6) δ 10.74 (br, 1H), 8.34-8.15 (m, 2H), 7.63-7.60 (m, 2H), 7.45 (t, 2H, J = 7.6), 7.32 (t, 1H, J = 7.2 Hz), 7.24-7.20 (m, 1H), 6.96-6.94 (m, 2H), 4.71 (bs, 1H), 3.57-3.30 (m, 8H), 1.92 (bs, 4H); HRMS (ESI): m/z calcd for $C_{21}H_{24}N_6O_2$ $[M+1]^+$ 393.2039, found 393.2050. **50**¹H NMR (400 MHz, DMSO- d_6) δ 8.67 (s, 1H), 7.34-7.26 (m, 1H), 7.06-6.93 (m, 3H), 4.74-4.64 (m, 1H), 4.20-4.12 (m, 2H), 3.58-3.31 (m, 8H), 1.93 (bs, 4H), 1.42 (t, 3H, J = 7.0 Hz); HRMS (ESI): m/z calcd for $C_{17}H_{23}ClN_6O_2$ $[M+1]^+$ 379.1649, found 379.1648. **51**¹H NMR (400 MHz, DMSO- d_6) δ 8.69 (d, 1H, J = 2.3 Hz), 7.31-7.23 (m, 1H), 7.07-6.90 (m, 3H), 4.72-4.67 (m, 2H), 3.57-3.34 (m, 8H), 1.93 (bs, 4H), 1.34 (d, 6H, J = 5.3 Hz); HRMS (ESI): m/z calcd for $C_{18}H_{25}ClN_6O_2$ $[M+1]^+$ 393.1806, found 393.1815. **52**¹H NMR (400 MHz, DMSO- d_6) δ 8.69 (s, 1H), 7.34-7.25 (m, 1H), 7.12 (d, 1H, J = 8.6 Hz), 7.04-6.92 (m, 2H), 4.73-4.67 (m, 1H), 3.57-3.31 (m, 8H), 1.93 (bs, 4H), 1.40 (s, 9H); HRMS (ESI): m/z calcd for $C_{19}H_{27}ClN_6O_2$ $[M+1]^+$ 407.1962, found 407.1966. **53**¹H NMR (400 MHz, DMSO- d_6) δ 8.97-8.86 (m, 1H), 7.85 (d, 2H, J = 8.6 Hz), 7.25 (t, 2H, J = 7.8 Hz), 6.92 (t, 1H, J = 7.4 Hz), 6.69 (bs, 1H), 4.76-4.66 (m, 1H), 3.57-3.31 (m, 8H), 1.91 (bs, 4H); HRMS (ESI): m/z calcd for $C_{15}H_{20}N_6O$ $[M+1]^+$ 301.1777, found 301.1774

- (18). **GC enzyme assay.** Assays were conducted using recombinant GC (Cerezyme®, Genzyme Co, Cambridge, MA) and Resorufin- β -D-Glucopyranoside (K_m = 28 μ M) in an assay buffer composed of 50 mM citric acid/ KH_2PO_4 , pH 5.9, 10 mM sodium taurocholate and 0.01% Tween-20. GC in assay buffer was added to a 1536-well black plate at 2 μ l/well, followed by addition of 23 nL of compound in DMSO with a pin-tool station (Kalypsys, San Diego). After 5 min at RT (~21°C), 1 μ l/well of substrate was added and incubated for 20 min at RT. Fluorescence intensity was measured at an excitation of 570 ($\pm$ 10) nm and an emission of 610 ($\pm$ 10) nm. The final concentrations of enzyme and substrate were 1.9 nM and 30 μ M, respectively. **Enzyme selectivity assays.** Three

additional hydrolases and their substrates, α -glucosidase (from rice) and 4-methylumbelliferyl α -D-glucopyranoside (4MU- α -Glc), α -galactosidase (from coffee beans) and 4-methylumbelliferyl α -D-galactopyranoside (4MU- α -Gal), β -N-acetylglucosaminidase (from bovine kidney) (HEX) and 4-methylumbelliferyl N-acetyl- β -D-glucosaminide (4MU- β -GSM) were obtained from Sigma-Aldrich. The buffer for all three enzyme assays consisted of 50 mM citric acid/KH₂PO₄, pH 4.5, 10 mM sodium taurocholate and 0.01% Tween-20. The final enzyme concentrations for α -glucosidase, α -galactosidase and β -N-acetylglucosaminidase were 8, 1 and 8 nM, respectively. The substrate concentrations were similar to the K_m values for these related enzymes, at 0.4, 0.16 and 0.2 mM, respectively

Figure 1.

Compound structures of previously reported inhibitors of glucocerebrosidase including 2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol (**1**), *N*-(4-methyl-2-morpholinoquinolin-6-yl)cyclohexanecarboxamide (**2**) and *N*-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-(phenylsulfonamido)benzamide (**3**) and *N*-butyl-deoxynojirimycin (Miglustat) (**4**).

Figure 2. Selective inhibition of glucocerebrosidase (◇), α-glucosidase (◆), α-galactosidase (Δ) and β-hexosaminidase (▲) by 37. Data represents the collective results of three independent experiments performed in triplicate.

^a Reagents and conditions: Method A. (i) substituted ArNH₂ (1 equiv), ACN, r.t. 4 h; (ii) substituted amine (3.3 equiv), Hunig's base, DMA, r.t. 10 min.; (iii) substituted amine (5-10 equiv), r.t. 4-8 h. Method B. (i) substituted ArNH₂ (1 equiv), Hunig's base, ACN, r.t. 4 h; (ii) substituted amine (1.05 equiv), Hunig's base, DMA, r.t. 10 min.; (iii) substituted amine (5-10 equiv), r.t. 4-8 h.

Scheme 1.

Table 1
SAR surrounding the ethanolamine moiety of the core triazine scaffold

	Analogue #	R	R'	GC inhibitors IC ₅₀ (μM) and SD*
1	-NHCH ₂ CH ₂ OH	2-OMe, 5-Cl	0.70 ± 0.08
	5	-NHCH ₂ CH ₂ OCH ₃	2-OMe, 5-Cl	inactive
	6	-N(CH ₂ CH ₂ OH) ₂	2-OMe, 5-Cl	inactive
	7	-NHCH ₂ CH ₂ CH ₂ CH ₃	2-OMe, 5-Cl	7.77 ± 0.33
	8	-NHCH ₂ Ph	2-OMe, 5-Cl	inactive
	9	-NHCH ₂ (2-furanyl)	2-OMe, 5-Cl	inactive
	10	-NH ₂	2-OMe, 5-Cl	inactive
	11	-NHCH ₂ CH ₂ NHCOCH ₃	2-OMe	inactive
	12	-NHCH ₂ CH(OH)CH ₃	2-OMe	20.70
	13	-NHCH ₂ CH(OH)CH ₂ Ph	2-OMe	6.80 ± 0.83
	14	-NHCH ₂ CONH ₂	2-OMe	inactive
	15	-NHCH ₂ CH ₂ CH ₂ CH ₂ OH	2-OMe	inactive
	16	-NHCH ₂ COOMe	2-OMe	inactive

* error represents the standard deviation determined from three separate experiments.

Table 2
SAR surrounding the pyrrolidine moiety of the core triazine scaffold

	Analogue #	X	R'	GC inhibitors IC ₅₀ (μM) and SD *
1	pyrrolidin-1-yl	2-OMe, 5-Cl	0.70 ± 0.08
	17	morpholin-1-yl	2-OMe, 5-Cl	12.13
	18	<i>N,N</i> -diethylamino	2-OMe, 5-Cl	inactive
	19	piperidin-1-yl	2-OMe, 5-Cl	31.10
	20	azepan-1-yl	2-OMe, 5-Cl	inactive
	21	<i>N</i> -(<i>n</i> -butyl)amino	2-OMe	6.1 ± 0.51
	22	<i>N</i> -benzylamino	2-OMe	18.80
	23	3,3-difluoropyrrolidin-1-yl	2-OMe	7.75 ± 0.82
	24	azetidin-1-yl	2-OMe	2.31 ± 0.28

* error represents the standard deviation determined from three separate experiments.

Table 3
SAR surrounding the aniline moiety of the core triazine scaffold

	Analogue #	R'	GC inhibitors IC ₅₀ (μM) and SD [*]
1	2-OMe, 5-Cl	0.70 ± 0.08
	25	2-Me	3.94 ± 0.13
	26	3-Me	6.19 ± 0.46
	27	4-Me	10.04
	28	2-Cl	28.97
	29	3-Cl	6.69 ± 0.27
	30	4-Cl	6.34 ± 0.06
	31	2-OMe	1.08 ± 0.13
	32	3-OMe	8.25 ± 0.21
	33	4-OMe	8.80 ± 0.64
	34	2-OH	2.00 ± 0.14
	35	2-OEt	0.77 ± 0.04
	36	2-OPh	21.67
	37	2- <i>i</i> -Bu	0.33 ± 0.06
	38	2-OBn	31.4
	39	2-OCF ₃	3.34 ± 0.06
	40	2-SMe	2.39 ± 0.09
	41	2-OMe, 5-OMe	1.53 ± 0.08
	42	2-OMe, 4-OMe	4.90 ± 0.13
	43	2-OMe, 5-CF ₃	2.65 ± 0.14
	44	2-OMe, 5-Ph	2.22 ± 0.04
	45	2-NO ₂	inactive
	46	2-CONH ₂	inactive
	47	2-NHCOCH ₃	inactive
	48	2-OH, 5-Cl	0.73 ± 0.09
	49	2-OH, 5-Ph	0.37 ± 0.05
	50	2-OEt, 5-Cl	0.96 ± 0.02
	51	2- <i>i</i> Pr, 5-Cl	3.44 ± 0.08
	52	2- <i>i</i> Bu, 5-Cl	1.04 ± 0.05
	53	H	16.47

* error represents the standard deviation determined from three separate experiments.